Market research
CN2.F Catalyst Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 17.96
- Analyst target
- 8.3
- Dividend yield
- Not available
- Beta
- 0.74
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US14888U1016
- Market cap
- 3B
- P/E ratio
- 17.96
- Analyst target
- 8.3
- Dividend yield
- Not available
- Beta
- 0.74
About
About Catalyst Pharmaceuticals, Inc
Catalyst Pharmaceuticals, Inc. operates as a biopharmaceutical company engaged in developing and commercializing novel medicines for patients living with rare diseases. It offers Firdapse for the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of Duchenne muscular dystrophy. Catalyst Pharmaceuticals, Inc. was formerly known as Catalyst Pharmaceutical Partners Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. The company was founded in 2002 and is based in Coral Gables, Florida. As of July 15, 2026, Catalyst Pharmaceuticals, Inc. operates as a subsidiary of Angelini Pharma S.p.a.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CN2.F discussion.
5 years, 5 months ago
Catalyst Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 29.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Catalyst Pharmaceuticals, Inc's total revenue rose by 3.0% to $31M since the same quarter in the previous year.
Its net income has increased by 44.2% to $11M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.6% to $13M since the same quarter in the previous year.
Based on the above factors, Catalyst Pharmaceuticals, Inc gets an overall score of 5/5.